hanchorbio
(2)
Scott Liu and the work between the milestones
Before he founded HanchorBio, Scott Liu spent years making quality somebody’s daily responsibility. His career across laboratories, boardrooms and two biotech ventures offers a less glamorous, more revealing account of how a company gets built.
Alvin Luk
Alvin Luk is a biotech executive, neuroscientist and entrepreneur with more than three decades in global drug development. He is President & Chief Medical Officer (Group) and U.S. CEO of HanchorBio, a clinical-stage immunology and immuno-oncology company building Fc-based designer biologics, and co-founder and CEO of CRISPR gene-editing company HuidaGene Therapeutics. Across his career he has contributed to roughly two dozen approved products and more than 250 global regulatory submissions, including LUXTURNA, the first FDA-approved gene therapy. A 2025 TIME100 Health honoree, he wants to turn HanchorBio into the 'Genentech of Asia.'